HEMOSTASIS COAGULATION ROUTINE REAGENTS ANTICOAGULANT MONITORING DOAC DOAC NEUTRALIZATION
HEMOSTASIS COAGULATION ROUTINE REAGENTS AUXILIARY REAGENTS NEUTRALIZERS
DOAC-Stop™
DOAC-Stop can be used to efficiently extract all types of Direct Oral Anti-Coagulants (DOACs) including dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban and also argatroban from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism. This product is intended for use as an accessory IVD. For professional use only.
DOAC-Stop™ is now offered for simplifying diagnostic problems associated with DOACs. DOACs are known to interfere with almost all clotting tests to varying degrees and sometimes patients who need to be tested for underlying coagulation defects may also be on DOACs.
Specific antidotes for individual DOACs are being developed for therapeutic use but are not yet widely available for laboratory use. DOAC-Stop™ is first of its kind to extract all types of new Direct Oral Anti-Coagulant (DOACs) including dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban and also argatroban from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism.
It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 10 minutes. Unlike therapeutic additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results.
There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants. We guarantee a competitive price for our reagents.
Advantages
One mini-tab of DOAC Stop in 1.0mL of normal plasma spiked with 500ng/ml of dabigatran, edoxaban, betrixaban, rivaroxaban or apixaban will remove more than 95% of the DOAC within 5 minutes. There was no effect on the baseline APTTs after 3 hours further incubation. In 92 test plasma samples covering a range of abnormalities, 89 gave definitive results and 3 were equivocal after DOAC-Stop in view of patient complexity. A recent study on 135 DOAC-treated plasmas showed that DOAC Stop was mostly effective in overcoming the effects of dabigatran in 40 cases, apixaban in 38 cases, rivaroxaban 42 cases and edoxaban 15 cases on several thrombophilia screening tests. The incidence of false positive lupus anticoagulants fell from approximately 30% to zero. For additional information, contact your distributor for a copy of the Technical Documentation.
Informations
Therapeutic uses of DOACs are increasing. DOACs are known to interfere with almost all clotting tests to varying degrees. Specific antidotes for individual DOACs are being developed but are not yet widely available for laboratory use. DOAC-Stop is the first general agent available for solving the diagnostic problems associated with DOACs. After treatment with DOAC-Stop, plasma samples can be analysed for underlying coagulation defects such as factor deficiencies, heparin, lupus anticoagulant or other interfering antibodies
Documentation
Download the product sheetPrice list, safety data sheets and notices are accessible to our registered customers.
Neutralizing
References
| 20-HX9904-50 | Tablets | 1 x 50 | 50 tests |
| 20-HX9904-100 | Tablets | 1 x 100 | 100 tests |
